Brokers Set Expectations for Dicerna Pharmaceuticals Inc’s FY2018 Earnings (DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – B. Riley reduced their FY2018 earnings per share (EPS) estimates for Dicerna Pharmaceuticals in a report released on Tuesday, November 6th. B. Riley analyst M. Kumar now anticipates that the biopharmaceutical company will post earnings of ($0.95) per share for the year, down from their previous forecast of ($0.82). B. Riley currently has a “Buy” rating and a $21.00 price target on the stock. B. Riley also issued estimates for Dicerna Pharmaceuticals’ Q4 2018 earnings at ($0.23) EPS, Q1 2019 earnings at ($0.28) EPS, Q2 2019 earnings at ($0.28) EPS, Q3 2019 earnings at ($0.28) EPS, Q4 2019 earnings at ($0.28) EPS, FY2019 earnings at ($1.10) EPS, FY2020 earnings at ($0.10) EPS, FY2021 earnings at ($0.88) EPS and FY2022 earnings at ($0.03) EPS.

Other analysts have also recently issued reports about the company. Citigroup initiated coverage on Dicerna Pharmaceuticals in a research report on Thursday, September 13th. They set a “buy” rating and a $27.00 price target on the stock. SunTrust Banks increased their price target on Dicerna Pharmaceuticals to $20.00 and gave the stock a “buy” rating in a research report on Thursday, September 6th. Cowen reiterated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Wednesday, September 5th. BidaskClub cut Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 29th. Finally, Stifel Nicolaus increased their price target on Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 9th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $20.44.

Shares of Dicerna Pharmaceuticals stock opened at $14.72 on Thursday. The company has a market cap of $900.20 million, a PE ratio of -4.02 and a beta of 2.37. Dicerna Pharmaceuticals has a twelve month low of $6.80 and a twelve month high of $17.98.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.11). Dicerna Pharmaceuticals had a negative net margin of 1,418.01% and a negative return on equity of 63.24%. The firm had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.67 million.

A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. grew its holdings in Dicerna Pharmaceuticals by 13.8% in the 3rd quarter. BlackRock Inc. now owns 2,967,073 shares of the biopharmaceutical company’s stock worth $45,277,000 after buying an additional 359,178 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Dicerna Pharmaceuticals by 15.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 185,441 shares of the biopharmaceutical company’s stock worth $2,830,000 after buying an additional 24,543 shares in the last quarter. Alliancebernstein L.P. grew its holdings in Dicerna Pharmaceuticals by 137.3% in the 3rd quarter. Alliancebernstein L.P. now owns 29,900 shares of the biopharmaceutical company’s stock worth $456,000 after buying an additional 17,300 shares in the last quarter. Swiss National Bank grew its holdings in Dicerna Pharmaceuticals by 21.1% in the 3rd quarter. Swiss National Bank now owns 65,500 shares of the biopharmaceutical company’s stock worth $1,000,000 after buying an additional 11,400 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. bought a new position in Dicerna Pharmaceuticals in the 3rd quarter worth approximately $4,448,000. 74.46% of the stock is owned by institutional investors and hedge funds.

In related news, Director Brian K. Halak sold 564,300 shares of the stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $13.66, for a total value of $7,708,338.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian K. Halak sold 335,000 shares of the stock in a transaction that occurred on Tuesday, November 6th. The stock was sold at an average price of $13.33, for a total value of $4,465,550.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,161,228 shares of company stock worth $15,858,388 over the last quarter. Insiders own 19.85% of the company’s stock.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.

Read More: Book Value Per Share in Stock Trading

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply